K
Kura Oncology
A clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer. The company's pipeline includes a diverse portfolio of small molecule drug candidates that target cancer cells with specific genetic mutations.
Read full description
Kura's lead product candidate, ziftomenib, is a potent and selective inhibitor of the menin-KMT2A/MLL interaction for the treatment of genetically defined acute myeloid leukemia (AML) patients. The company is also advancing other clinical-stage programs, including tipifarnib for the treatment of head and neck squamous cell carcinoma (HNSCC) and other solid tumors.
The company's business model is centered on the research, development, and commercialization of its proprietary drug candidates. Kura Oncology collaborates with academic institutions and other biopharmaceutical companies to advance its pipeline and bring new cancer therapies to patients in need. The company's primary market is the global oncology market, with a focus on addressing unmet medical needs in specific patient populations.
At a glance
- Founded
- 2014
- Headquarters
- San Diego, United States
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later8 investors entered at this stage
EcoR1 Capital
ARCH Venture Partners
Nextech Invest
Foresite Capital
Osage University Partners
Avoro Capital Advisors
Bristol-Myers Squibb
Hercules Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kura Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kura Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.